 |
| Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Remibrutinib Open Label Roll-over Post-trial Access Protocol | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. | Novartis Pharmaceuticals | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A 52-week Study of Remibrutinib in IgE-mediated Food Allergy | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects | Novartis Pharmaceuticals | NA |
COMPLETED
(Sep 1, 2026)
| PHASE1 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) | Novartis Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | Novartis Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | Novartis Pharmaceuticals | NA |
TERMINATED
(Aug 1, 2026)
| PHASE3 |
| Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma | Novartis Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma | Novartis Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors | Novartis Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |
| A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Novartis Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | Novartis Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) | Novartis Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks | Novartis Pharmaceuticals | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) | Novartis Pharmaceuticals | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients | Novartis Pharmaceuticals | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia | Novartis Pharmaceuticals | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia | Novartis Pharmaceuticals | NA |
TERMINATED
(Jul 1, 2026)
| PHASE2 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia | Novartis Pharmaceuticals | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | Novartis Pharmaceuticals | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Novartis Pharmaceuticals | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Novartis Pharmaceuticals | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant | Novartis Pharmaceuticals | NA |
TERMINATED
(Jun 1, 2026)
| PHASE3 |
| Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma | Novartis Pharmaceuticals | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects | Novartis Pharmaceuticals | NA |
TERMINATED
(Jun 1, 2026)
| PHASE3 |
| Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | Novartis Pharmaceuticals | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE1, PHASE2 |
| Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | Novartis Pharmaceuticals | NA |
TERMINATED
(Jun 1, 2026)
| PHASE3 |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2) | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) | Novartis Pharmaceuticals | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| Phase 2 Study of Rapcabtagene Autoleucel in Myositis | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE2 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Novartis Pharmaceuticals | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1, PHASE2 |
| Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Novartis Pharmaceuticals | NA |
WITHDRAWN
(Jun 1, 2026)
| PHASE1, PHASE2 |
| Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE3 |
| Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan | Novartis Pharmaceuticals | NA |
COMPLETED
(May 1, 2026)
| PHASE2 |
| Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1) | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE3 |
| Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts | Novartis Pharmaceuticals | NA |
COMPLETED
(May 1, 2026)
| PHASE2 |
| Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE1 |
| Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia | Novartis Pharmaceuticals | NA |
RECRUITING
(May 1, 2026)
| PHASE3 |
| Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent | Novartis Pharmaceuticals | NA |
TERMINATED
(Apr 1, 2026)
| PHASE2 |
| Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | Novartis Pharmaceuticals | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | Novartis Pharmaceuticals | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE3 |
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | Novartis Pharmaceuticals | NA |
COMPLETED
(Mar 1, 2026)
| PHASE1 |
| An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab | Novartis Pharmaceuticals | NA |
COMPLETED
(Mar 1, 2026)
| PHASE3 |
| To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria | Novartis Pharmaceuticals | NA |
COMPLETED
(Mar 1, 2026)
| PHASE2 |
| An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE3 |
| A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. | Novartis Pharmaceuticals | NA |
COMPLETED
(Mar 1, 2026)
| PHASE1 |
| A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients | Novartis Pharmaceuticals | NA |
RECRUITING
(Mar 1, 2026)
| |
| Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Oct, 2024)
| PHASE2 |
| Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC | Novartis Pharmaceuticals | NA |
ACTIVE NOT RECRUITING
(Sep, 2024)
| PHASE4 |
| Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients | Novartis Pharmaceuticals | NA |
COMPLETED
(Jul, 2023)
| |
| The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients | Novartis Pharmaceuticals | NA |
COMPLETED
(Mar, 2023)
| PHASE4 |
| Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction | Novartis Pharmaceuticals | NA |
COMPLETED
(Mar, 2020)
| PHASE4 |
| Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction | Novartis Pharmaceuticals | NA |
COMPLETED
(Feb, 2019)
| PHASE3 |
| Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension | Novartis Pharmaceuticals | NA |
COMPLETED
(Oct, 2015)
| PHASE2 |
| Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection | Novartis Pharmaceuticals | NA |
COMPLETED
(Jul, 2012)
| PHASE3 |
